ClinicalTrials.gg
Not yet recruitingNCT06584071Updated Dec 16, 2024

A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

A Phase 1/2 interventional study of PM8002 and PM1009 in HCC and Liver Cancer, sponsored by Biotheus Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by Biotheus Inc. (part of BioNTech SE) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study to evaluate the preliminary efficacy, safety and pharmacokinetics of PM8002 combined with PM1009 in Patients with first-line Hepatocellular Carcinoma.

Read the detailed description

The study is divided into two parts. The first part is a phase Ib, single-arm study, which is planned to enroll 3-28 subjects.

The second part is a phase II randomized, parallel-controlled, four-arm, open-label study, which is planned to enroll approximately 120 subjects.

02

Conditions studied

  • HCC
  • Liver Cancer

Browse trials for

Keywords

  • first line
  • HCC
  • PM1009
  • PM8002
03

In context

Liver Neoplasms

1,346 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.

This study's planned enrollment of 140 is above the median of 47 across 928 interventional studies indexed under Liver Neoplasms.

Browse Liver Neoplasms studies →

Lead sponsor

Biotheus Inc. is the lead sponsor of 18 studies on the registry; 8 are open to participants now.

First submitted before Biotheus Inc. became part of BioNTech SE.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in clinical studies;
  2. Male or female, aged ≥ 18 years;
  3. Pathologically or clinically confirmed (according to AASLD), unresectable locally advanced and/or HCC;
  4. liver function score ≤7;
  5. No prior systemic therapy for locally advanced or metastatic and/or unresectable HCC;
  6. At least 1 ;
  7. Adequate organ function;
  8. score of 0 to 1;
  9. ≥ 12 weeks;

Exclusion criteria

Exclusion Criteria:

  1. confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma and other components;
  2. History of serious allergic diseases;
  3. The toxicity of previous anti-tumor therapy has not been alleviated;
  4. History of severe cardiovascular diseases within 6 months;
  5. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;
  6. History of hematopoietic stem cell transplantation or allogeneic organ transplantation;
  7. History of alcohol abuse, psychotropic substance abuse or drug abuse;
  8. (HIV) infection or known acquired immunodeficiency syndrome;
  9. Pregnant or lactating women;
  10. Other conditions considered unsuitable for this study by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Cohort 1- combination treatment

    Combination regimen:PM8002 combined with PM1009. The drugs are administered on the first day every 3 weeks (Q3W), until disease progression or intolerable toxicity or patient withdrawal or study discontinuation(Whichever occurs first).

    Drug: PM8002 · Drug: PM1009

  • Experimental
    Cohort 2- combination treatment

    Combination regimen:PM8002 combined with PM1009(low dose). The drugs are administered on the first day every 3 weeks (Q3W), until disease progression or intolerable toxicity or patient withdrawal or study discontinuation(Whichever occurs first).

    Drug: PM8002 · Drug: PM1009

  • Experimental
    Cohort 3- monotherapy

    PM8002 administered on the first day every 3 weeks (Q3W), until disease progression or intolerable toxicity or patient withdrawal or study discontinuation(Whichever occurs first).

    Drug: PM8002

  • Active comparator
    Cohort 4

    Combination regimen:atezolizumab combined with bevacizumab. The drugs are administered on the first day every 3 weeks (Q3W), until disease progression or intolerable toxicity or patient withdrawal or study discontinuation(Whichever occurs first).

    Drug: atezolizumab · Drug: bevacizumab

Interventions

  • DrugPM8002

    PM8002 via IV infusion, Q3W

  • DrugPM1009

    PM8002 via IV infusion, Q3W

  • atezolizumab,1200mg, via IV infusion, Q3W

  • bevacizumab,15mg/kg, via IV infusion, Q3W

06

What researchers measure

Primary outcomes

  1. Objective response rate(ORR)

    ORR is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  2. Optimal dosing regimen of PM8002 in combination with PM1009

    To determine the dosing regimen of PM8002 in combination with PM1009

    Time frame: Up to approximately 2 years

  3. Treatment related adverse events (TRAEs)

    The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0

    Time frame: Up to 30 days after last treatment

Secondary outcomes

  1. Objective response rate(ORR)(mRECIST)

    ORR is the proportion of subjects with complete response (CR) or partial response (PR), based on mRECIST

    Time frame: Up to approximately 2 years

  2. Disease control rate (DCR)

    DCR is defined as the proportion of subjects with complete response (CR), partial response (PR) or stable disease (SD) based on RECIST v1.1 and mRECIST

    Time frame: Up to approximately 2 years

  3. Duration of response (DOR)

    DOR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first

    Time frame: Up to approximately 2 years

  4. Progression free survival (PFS)

    PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first

    Time frame: Up to approximately 2 years

  5. Overall survival (OS)

    OS is the time from the date of randomization or first dosing date to death due to any cause

    Time frame: Up to approximately 2 years

  6. Maximum observed concentration [Cmax]

    To evaluate the Cmax of Combination regimen .

    Time frame: Up to 30 days after last treatment

  7. Time to Cmax [Tmax]

    To evaluate the Tmax of Combination regimen .

    Time frame: Up to 30 days after last treatment

  8. Minimum observed concentration [Cmin]

    To evaluate the Cmin of Combination regimen .

    Time frame: Up to 30 days after last treatment

  9. Area under the concentration-time curve [AUC0-last]

    To evaluate the AUC0-last of Combination regimen .

    Time frame: Up to 30 days after last treatment

  10. AUC to the end of the dosing period(AUC0-tau)

    To evaluate the AUC0-tau of Combination regimen .

    Time frame: Up to 30 days after last treatment

  11. Apparent terminal elimination half-life (t1/2)

    To evaluate the t1/2 of Combination regimen .

    Time frame: Up to 30 days after last treatment

  12. Anti-drug antibody (ADA)

    To evaluate the incidence of ADA to PM8002

    Time frame: Up to 30 days after last treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — The data will be published or presented for publications (poster, abstract,articles or papers) or any presentations

Time frame: After the trial completed

Access criteria: NCI is committed to sharing data in accordance with NIH policy.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Oct 2026, 22 months later.

Of 33 phase 1/2 interventional studies under Liver Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 72. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Sep 4, 2024
StartEst.
Dec 2024
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2027
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06584071
Lead sponsor
Biotheus Inc.
Responsible party
Sponsor
First posted
Sep 4, 2024
Start date
Dec 2024 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Dec 16, 2024

Study contacts

Xuelian Xing
Contact
xing.xl@biotheus.com
+86 021 32120207
Jia Fan
principal investigator · Zhong Shan Hospital, Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion